Search results
Results from the WOW.Com Content Network
Tier 3: These are typically nonpreferred, brand-name medications that have a higher copayment. Specialty tier: These are high cost prescription drugs that have the highest copayment.
The main discussion of these abbreviations in the context of drug prescriptions and other medical prescriptions is at List of abbreviations used in medical prescriptions. Some of these abbreviations are best not used, as marked and explained here.
For example, under a 3-tier formulary, the first tier typically includes generic drugs with the lowest cost sharing (e.g., 10% coinsurance), the second includes preferred brand-name drugs with higher cost sharing (e.g., 25%), and the third includes non-preferred brand-name drugs with the highest cost-sharing (e.g., 40%).
take (often effectively a noun meaning "prescription"—medical prescription or prescription drug) rep. repetatur: let it be repeated s. signa: write (write on the label) s.a. secundum artem: according to the art (accepted practice or best practice) SC subcutaneous "SC" can be mistaken for "SL," meaning sublingual. See also SQ: sem. semen seed ...
Oral administration of a liquid. In pharmacology and toxicology, a route of administration is the way by which a drug, fluid, poison, or other substance is taken into the body. [1] Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration ...
A kardex (plural kardexes) is a genericised trademark for a medication administration record. [2] The term is common in Ireland and the United Kingdom.In the Philippines, the term is used to refer the old census charts of the charge nurse usually used during endorsement, in which index cards are used, but has been gradually been replaced by modern health data systems and pre-printed charts and ...
This is a new direction in managing the high costs of specialty pharmaceuticals and not without challenges. One of the barriers is strict regulation by the Food and Drug Administration of what pharmaceutical manufacturers may communicate to the public, limiting that communication to formulary committees for managed care, for example. [73 ...
The drug or other substance has a currently accepted medical use in treatment in the United States. Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III. The complete list of Schedule IV substances is as follows.